Japan Tissue Engineering（7774）株式概要ジャパン・ティッシュ・エンジニアリング株式会社は、日本で再生医療事業を行っている。 詳細7774 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析JP市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見る7774 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥627.00194.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-734m3b2016201920222025202620282031Revenue JP¥2.3bEarnings JP¥424.9mAdvancedSet Fair ValueView all narrativesJapan Tissue Engineering Co., Ltd. 競合他社Pharma Foods InternationalSymbol: TSE:2929Market cap: JP¥19.2bHeartseedSymbol: TSE:219AMarket cap: JP¥36.6bReproCELLSymbol: TSE:4978Market cap: JP¥13.4bKidswell BioSymbol: TSE:4584Market cap: JP¥8.4b価格と性能株価の高値、安値、推移の概要Japan Tissue Engineering過去の株価現在の株価JP¥627.0052週高値JP¥883.0052週安値JP¥448.00ベータ0.581ヶ月の変化17.42%3ヶ月変化-21.23%1年変化7.18%3年間の変化3.13%5年間の変化-8.47%IPOからの変化59.14%最新ニュースReported Earnings • May 06Full year 2026 earnings released: JP¥18.07 loss per share (vs JP¥6.28 loss in FY 2025)Full year 2026 results: JP¥18.07 loss per share (further deteriorated from JP¥6.28 loss in FY 2025). Revenue: JP¥2.18b (down 11% from FY 2025). Net loss: JP¥734.0m (loss widened 188% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • May 01Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026.Reported Earnings • Jan 31Third quarter 2026 earnings released: JP¥4.56 loss per share (vs JP¥3.08 loss in 3Q 2025)Third quarter 2026 results: JP¥4.56 loss per share (further deteriorated from JP¥3.08 loss in 3Q 2025). Revenue: JP¥511.0m (down 6.3% from 3Q 2025). Net loss: JP¥185.0m (loss widened 48% from 3Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.分析記事 • Dec 30Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is LackingThe Japan Tissue Engineering Co., Ltd. ( TSE:7774 ) share price has done very well over the last month, posting an...分析記事 • Dec 29We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash BurnEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.最新情報をもっと見るRecent updatesReported Earnings • May 06Full year 2026 earnings released: JP¥18.07 loss per share (vs JP¥6.28 loss in FY 2025)Full year 2026 results: JP¥18.07 loss per share (further deteriorated from JP¥6.28 loss in FY 2025). Revenue: JP¥2.18b (down 11% from FY 2025). Net loss: JP¥734.0m (loss widened 188% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • May 01Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026.Reported Earnings • Jan 31Third quarter 2026 earnings released: JP¥4.56 loss per share (vs JP¥3.08 loss in 3Q 2025)Third quarter 2026 results: JP¥4.56 loss per share (further deteriorated from JP¥3.08 loss in 3Q 2025). Revenue: JP¥511.0m (down 6.3% from 3Q 2025). Net loss: JP¥185.0m (loss widened 48% from 3Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.分析記事 • Dec 30Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is LackingThe Japan Tissue Engineering Co., Ltd. ( TSE:7774 ) share price has done very well over the last month, posting an...分析記事 • Dec 29We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash BurnEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 02Second quarter 2026 earnings released: JP¥3.17 loss per share (vs JP¥0.34 loss in 2Q 2025)Second quarter 2026 results: JP¥3.17 loss per share (further deteriorated from JP¥0.34 loss in 2Q 2025). Revenue: JP¥571.6m (down 21% from 2Q 2025). Net loss: JP¥128.6m (loss widened JP¥114.7m from 2Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 31First quarter 2026 earnings released: JP¥5.96 loss per share (vs JP¥5.20 loss in 1Q 2025)First quarter 2026 results: JP¥5.96 loss per share (further deteriorated from JP¥5.20 loss in 1Q 2025). Revenue: JP¥426.0m (down 3.7% from 1Q 2025). Net loss: JP¥242.0m (loss widened 15% from 1Q 2025). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Jul 21+ 2 more updatesJapan Tissue Engineering Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2026 results on Oct 31, 2025Reported Earnings • Jun 24Full year 2025 earnings released: JP¥6.29 loss per share (vs JP¥3.52 profit in FY 2024)Full year 2025 results: JP¥6.29 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.3m (down 279% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 14Japan Tissue Engineering Co., Ltd. to Report Q1, 2026 Results on Jul 30, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2026 results on Jul 30, 2025Reported Earnings • May 01Full year 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.52 profit in FY 2024)Full year 2025 results: JP¥6.28 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.0m (down 278% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 30Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025.分析記事 • Apr 21Market Might Still Lack Some Conviction On Japan Tissue Engineering Co., Ltd. (TSE:7774) Even After 38% Share Price BoostJapan Tissue Engineering Co., Ltd. ( TSE:7774 ) shareholders would be excited to see that the share price has had a...New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Apr 06Here's Why We're Not Too Worried About Japan Tissue Engineering's (TSE:7774) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Mar 20Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2025 Results on Apr 30, 2025Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2025 results on Apr 30, 2025Reported Earnings • Feb 01Third quarter 2025 earnings released: JP¥3.08 loss per share (vs JP¥1.03 loss in 3Q 2024)Third quarter 2025 results: JP¥3.08 loss per share (further deteriorated from JP¥1.03 loss in 3Q 2024). Revenue: JP¥545.0m (up 1.1% from 3Q 2024). Net loss: JP¥125.0m (loss widened 198% from 3Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Dec 07Japan Tissue Engineering Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2025 results on Jan 31, 2025Reported Earnings • Nov 02Second quarter 2025 earnings released: JP¥0.34 loss per share (vs JP¥0.59 loss in 2Q 2024)Second quarter 2025 results: JP¥0.34 loss per share (improved from JP¥0.59 loss in 2Q 2024). Revenue: JP¥718.7m (up 23% from 2Q 2024). Net loss: JP¥13.9m (loss narrowed 42% from 2Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Aug 31Japan Tissue Engineering Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2025 results on Oct 31, 2024Reported Earnings • Aug 01First quarter 2025 earnings released: JP¥5.20 loss per share (vs JP¥0.32 profit in 1Q 2024)First quarter 2025 results: JP¥5.20 loss per share (down from JP¥0.32 profit in 1Q 2024). Revenue: JP¥442.0m (down 33% from 1Q 2024). Net loss: JP¥211.0m (down JP¥224.0m from profit in 1Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Aug 01Little Excitement Around Japan Tissue Engineering Co., Ltd.'s (TSE:7774) RevenuesJapan Tissue Engineering Co., Ltd.'s ( TSE:7774 ) price-to-sales (or "P/S") ratio of 10.1x might make it look like a...Reported Earnings • Jun 23Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023)Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023)Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Mar 06The Market Lifts Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares 35% But It Can Do MoreJapan Tissue Engineering Co., Ltd. ( TSE:7774 ) shareholders have had their patience rewarded with a 35% share price...お知らせ • Mar 03Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2024Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2024 results on Apr 30, 2024Reported Earnings • Feb 02Third quarter 2024 earnings released: JP¥1.03 loss per share (vs JP¥5.02 loss in 3Q 2023)Third quarter 2024 results: JP¥1.03 loss per share (improved from JP¥5.02 loss in 3Q 2023). Revenue: JP¥539.0m (up 14% from 3Q 2023). Net loss: JP¥42.0m (loss narrowed 79% from 3Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Dec 01Japan Tissue Engineering Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2024 results on Jan 30, 2024Reported Earnings • Nov 02Second quarter 2024 earnings released: JP¥0.59 loss per share (vs JP¥3.77 loss in 2Q 2023)Second quarter 2024 results: JP¥0.59 loss per share (improved from JP¥3.77 loss in 2Q 2023). Revenue: JP¥584.0m (up 6.2% from 2Q 2023). Net loss: JP¥24.0m (loss narrowed 84% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Sep 01Japan Tissue Engineering Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2024 results on Oct 31, 2023Reported Earnings • Aug 01First quarter 2024 earnings released: EPS: JP¥0.32 (vs JP¥6.60 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.32 (up from JP¥6.60 loss in 1Q 2023). Revenue: JP¥662.0m (up 57% from 1Q 2023). Net income: JP¥13.0m (up JP¥281.0m from 1Q 2023). Profit margin: 2.0% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Jun 18Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022)Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Jun 11Japan Tissue Engineering Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023Reported Earnings • Apr 29Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022)Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • Jan 28Third quarter 2023 earnings released: JP¥5.03 loss per share (vs JP¥1.80 loss in 3Q 2022)Third quarter 2023 results: JP¥5.03 loss per share (further deteriorated from JP¥1.80 loss in 3Q 2022). Revenue: JP¥471.4m (down 23% from 3Q 2022). Net loss: JP¥204.3m (loss widened 180% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.お知らせ • Jan 28Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 1,971 million. Operating loss to be JPY 787 million. Net loss to be JPY 789 million. Net loss per share to be JPY 19.43.お知らせ • Dec 05Japan Tissue Engineering Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2023 results on Jan 31, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Toshiyuki Masai was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 01Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 2,540 million. Operating loss to be JPY 389 million. Net loss to be JPY 388 million. Net loss per share to be JPY 9.57.Reported Earnings • Nov 01Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: JP¥550.2m (up 9.6% from 2Q 2022). Net loss: JP¥153.4m (loss widened 11% from 2Q 2022).お知らせ • Sep 02Japan Tissue Engineering Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2023 results at 3:00 PM, Tokyo Standard Time on Oct 31, 2022Reported Earnings • Jul 28First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: JP¥422.7m (down 12% from 1Q 2022). Net loss: JP¥268.2m (loss widened 108% from 1Q 2022).お知らせ • Jul 28Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the period, the company expected net sales of JPY 2,540 million, operating loss of JPY 389 million, net loss of JPY 388 million and net loss per share of JPY 9.57.Price Target Changed • Jul 23Price target decreased to JP¥1,200Down from JP¥1,760, the current price target is provided by 1 analyst. New target price is 95% above last closing price of JP¥615. Stock is down 14% over the past year. The company posted a net loss per share of JP¥12.24 last year.Reported Earnings • Jun 19Full year 2022 earnings released: JP¥12.26 loss per share (vs JP¥11.48 loss in FY 2021)Full year 2022 results: JP¥12.26 loss per share (down from JP¥11.48 loss in FY 2021). Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.お知らせ • Jun 10Japan Tissue Engineering Co., Ltd. to Report Q1, 2023 Results on Jul 27, 2022Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2023 results at 3:00 PM, Tokyo Standard Time on Jul 27, 2022お知らせ • Apr 27Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of ¥2,540 million, operating loss of ¥389 million and net loss of ¥388 million or ¥9.57 per share.Reported Earnings • Apr 27Full year 2022 earnings releasedFull year 2022 results: Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021).Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Managing Executive Officer & Director Hiroaki Kaneko was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 08Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2022 Results on Apr 26, 2022Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2022 results on Apr 26, 2022Reported Earnings • Feb 01Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: JP¥615.5m (up 32% from 3Q 2021). Net loss: JP¥73.6m (loss narrowed 47% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Feb 01Japan Tissue Engineering Co., Ltd. Announces Earnings Guidance for the Fiscal Year Ending March 31, 2022Japan Tissue Engineering Co., Ltd. announced earnings guidance for the fiscal year ending March 31, 2022. For the full Fiscal Year, the company expects sales of JPY 2,260 million, Operating loss of JPY 450 million, net loss of JPY 449 million and net loss per share of JPY 11.06.お知らせ • Nov 25Japan Tissue Engineering Co., Ltd. Announces Start of Clinical Trial for Allogeneic Cultured EpidermisJapan Tissue Engineering Co., Ltd. announced that it submitted notification of the clinical trial plan for Allogeneic Cultured Epidermis (development name: "Allo-JaCE03") to the Pharmaceuticals and Medical Devices Agency today. J-TEC will acquire knowledge and know-how about medical devices through the development of "Allo-JaCE03" and develop new business in fields that use allogeneic cells (cells from other people). With the vision of "creating a future for regenerative medicine", J-TEC is promoting the creation of a regenerative medicine industry and contributing to the improvement of patient quality of life (QOL) by continuously developing and marketing new regenerative medical products and medical devices, in addition to promoting the spread of J-TEC's existing products. " Allo-JaCE03" is dried epidermal cell sheet derived from healthy human skin. Through reconstitution, it returns to the resilient physical properties it had before drying. Its high degree of biocompatibility makes it suitable for use in the promotion of early wound healing. Clinical Trial Summary: The purpose of this clinical trial is to verify the efficacy and confirm the safety of "Allo-JaCE03" in patients with deep dermal burn (DDB), which is a typical skin defect disorder. J-TEC plans to conduct the clinical trial at a total of 5 facilities, including Kyoto University Hospital. Product Features: Because the raw material is allogeneic cells, systematic mass-production of a product that meets certain quality standards is possible. The dried form of this cultured product means that it can be stored at room temperature for long periods of time. Medical institutions can stock it as a ready-made product (one that is manufactured and stored in advance so that it can be used without delay when needed). This product is a medical device that does not contain living cells. J-TEC is taking advantage of the product features of allogeneic origin and dried form to accelerate deployment not only within Japan but also to overseas markets.Reported Earnings • Oct 31Second quarter 2022 earnings released: JP¥3.40 loss per share (vs JP¥2.41 loss in 2Q 2021)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2022 results: Revenue: JP¥502.0m (down 6.9% from 2Q 2021). Net loss: JP¥138.0m (loss widened 41% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Sep 16Japan Tissue Engineering Co., Ltd. Announces Approval of Autologous Cultured Oral Mucosal Epithelium Ocural for NHI ListingJapan Tissue Engineering Co., Ltd. announces the approval of Autologous Cultured Oral Mucosal Epithelium "Ocural" for inclusion in the National Health Insurance price list effective December 1, 2021, at the general meeting of Central Social Insurance Medical Council (Chuikyo) held today. Ocural" is expected to be of benefit as a new treatment method for patients who have had marked declines in visual acuity owing to extensive corneal damage from limbal stem cell deficiency. With the corporate vision of "creating a future for regenerative medicine", J-TEC is building a regenerative medicine industry while contributing to the improvement of patients' quality of life (QOL) by continually developing and launching new regenerative medical products in addition to promoting the spread of its existing products.Reported Earnings • Jul 31First quarter 2022 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: JP¥478.3m (up 27% from 1Q 2021). Net loss: JP¥129.5m (loss narrowed 26% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.お知らせ • Jun 18Japan Tissue Engineering Co., Ltd. Announces Approval Obtained for Autologous Cultured Oral Mucosal Epithelium “Ocural”Japan Tissue Engineering Co., Ltd. announce that marketing approval was obtained for Autologous Cultured Oral Mucosal Epithelium "Ocural" on June 11, 2021. "Ocural" is a product for the treatment of limbal stem cell deficiency, and it is the world's first regenerative medical product using oral mucosal epithelial cells to treat this disease. This product will be manufactured in Japan and was developed through the practical application of technology developed by Prof. Kohji Nishida of the Department of Ophthalmology, Osaka University Graduate School of Medicine. It will be Japan's second regenerative medical product in the ophthalmology field, following Autologous Cultured Corneal Epithelium "Nepic", for which marketing approval was obtained in March 2020. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for Autologous Cultured Epidermis "JACE", which became Japan's first regenerative medical product, in 2007, and began marketing it in 2009. J-TEC went on to obtain marketing approval for Autologous Cultured Cartilage "JACC" in 2013 and Autologous Cultured Corneal Epithelium "Nepic" in March of 2020. "JACC" and "Nepic" were Japan's first regenerative medical products in the orthopedic surgery and ophthalmology fields, respectively. Through the practical application of "Ocural" in addition to "Nepic", J-TEC has made it possible to provide therapies for corneal epithelial diseases, for which curative treatment methods previously did not exist. J-Tec is promoting the industrialization of regenerative medicine and contributing to the improvement of patients' quality of life (QOL) by further strengthening sales of its existing products and accelerating the development of new regenerative medical products.お知らせ • May 25Japan Tissue Engineering Co., Ltd. Announces Marketing Approval of Autologous Cultured Oral Mucosal Epithelial Cell SheetJapan Tissue Engineering Co., Ltd. announced that marketing approval of autologous cultured oral mucosal epithelial cell sheet (Development Name: COMET01) for the treatment of limbal stem cell deficiency (LSCD) *1 has been reviewed and acknowledged at today's meeting of the Regenerative Medical Products and Biological Technology Subcommittee of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council. COMET01 is epithelial cell sheet derived from human (autologous) oral mucosa. It is prepared by harvesting oral mucosal tissue from the patient and then cultivating the isolated cells. The purpose of this product is to repair defective corneal epithelium by transplanting the sheet onto the ocular surface, where the patient's own oral mucosal epithelial cells become engrafted and epithelialize. COMET01 is a promising new treatment method for patients who have extensive damage to the cornea of both eyes and markedly reduced visual acuity owing to LSCD. COMET01 was designated a regenerative medical product for orphan diseases *2 -- specifically the treatment of LSCD -- in 2020. J-TEC introduced the transplantation technique for autologous cultured oral mucosal epithelial cell sheets developed by Professor Kohji Nishida of Graduate School of Medicine/Faculty of Medicine, Osaka University (Department of Neural and Sensory Organ Surgery (Department of Ophthalmology)) and has taken over the investigator-initiated trial conducted by Professor Nishida's group, conducting it in the form of a company-sponsored clinical trial of COMET01 since September of 2016. In September of 2020, J-TEC submitted an application for marketing approval of COMET01to the Ministry of Health, Labour and Welfare as Japan's second regenerative medical product in the ophthalmology field. Marketing of COMET01 is to be conducted by Nidek Co., Ltd. (Gamagori City, Aichi Prefecture; President and CEO, Motoki Ozawa), a maker of ophthalmology and optometry products. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for autologous cultured epidermis "JACE", Japan's first regenerative medical product, in 2007 and began marketing JACE in 2009. Marketing approval was then obtained for autologous cultured cartilage "JACC" in 2013 and for autologous cultured corneal epithelium "NEPIC" *3 in March of 2020. JACC was Japan's first regenerative medical product in the orthopedic surgery field, and NEPIC was the first in the ophthalmology field. Through the practical application of first NEPIC and then COMET01, J-TEC has succeeded in providing a treatment method for corneal epithelial diseases for which no curative therapy previously existed. By reinforcing sales of existing products and accelerating development of new regenerative medical products, J-TEC is promoting the development of regenerative medicine into an industry while also contributing to the improvement of patients' quality of life (QOL).Reported Earnings • May 01Full year 2021 earnings released: JP¥11.48 loss per share (vs JP¥7.07 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: JP¥2.26b (down 2.3% from FY 2020). Net loss: JP¥466.0m (loss widened 62% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Mar 04New 90-day high: JP¥802The company is up 24% from its price of JP¥649 on 04 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.分析記事 • Feb 02We Think Japan Tissue Engineering (TYO:7774) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Feb 01Third quarter 2021 earnings released: JP¥3.40 loss per share (vs JP¥2.24 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥466.4m (down 11% from 3Q 2020). Net loss: JP¥137.9m (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 01New 90-day high: JP¥739The company is up 12% from its price of JP¥662 on 02 November 2020. The Japanese market is also up 12% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 10.0% over the same period.お知らせ • Dec 19Japan Tissue Engineering Co., Ltd. to Report Q3, 2021 Results on Jan 29, 2021Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2021 results on Jan 29, 2021Reported Earnings • Nov 01First half earnings releasedOver the last 12 months the company has reported total losses of JP¥288.0m, with losses widening by 52% from the prior year. Total revenue was JP¥2.24b over the last 12 months, down 3.2% from the prior year.お知らせ • Sep 06Japan Tissue Engineering Co., Ltd. to Report Q2, 2021 Results on Oct 30, 2020Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2021 results on Oct 30, 2020お知らせ • Aug 04Japan Tissue Engineering Co., Ltd. Do Not Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021Japan Tissue Engineering Co., Ltd. does not provided earnings guidance for the fiscal year ending March 31, 2021. The company announced that the 2019 novel coronavirus infection has spread worldwide and has a great impact on the business environment in Japan and overseas. Since there are many uncertainties that will affect the company's business due to the spread of infection, it is difficult to reasonably calculate the business forecast for the fiscal year ending March 2021 at this point. The company will make an announcement as soon as the situation has settled and it is possible to calculate the earnings forecast.お知らせ • Jun 28Japan Tissue Engineering Co., Ltd. to Report Q1, 2021 Results on Jul 30, 2020Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2021 results on Jul 30, 2020株主還元7774JP BiotechsJP 市場7D8.3%3.1%3.6%1Y7.2%-20.6%41.3%株主還元を見る業界別リターン: 7774過去 1 年間で-20.6 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 7774は、過去 1 年間で41.3 % のリターンを上げたJP市場を下回りました。価格変動Is 7774's price volatile compared to industry and market?7774 volatility7774 Average Weekly Movement11.5%Biotechs Industry Average Movement9.4%Market Average Movement4.9%10% most volatile stocks in JP Market9.6%10% least volatile stocks in JP Market2.4%安定した株価: 7774の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7774の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1999204Kazuto Yamadawww.jpte.co.jpジャパン・ティッシュ・エンジニアリング株式会社は、日本国内で再生医療事業を展開している。再生医療等製品事業、再生医療等受託事業、研究開発支援事業を展開。自己培養表皮、軟骨、角膜上皮、口腔粘膜上皮を医療機関向けに提供し、医療に役立てている。また、組織工学に基づいた医療製品の提供も行っている。また、外用化粧品や医薬品の開発、皮膚や角膜の組織を用いた研究に用いるヒト3次元培養組織モデルの研究開発を行っている。さらに、再生医療の受託開発・製造サービスも提供している。同社は1999年に設立され、蒲郡市に本社を置く。ジャパン・ティッシュ・エンジニアリング株式会社は帝人株式会社の子会社として運営されている。もっと見るJapan Tissue Engineering Co., Ltd. 基礎のまとめJapan Tissue Engineering の収益と売上を時価総額と比較するとどうか。7774 基礎統計学時価総額JP¥26.07b収益（TTM）-JP¥734.00m売上高(TTM)JP¥2.18b11.7xP/Sレシオ-34.7xPER（株価収益率7774 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7774 損益計算書（TTM）収益JP¥2.18b売上原価JP¥916.00m売上総利益JP¥1.27bその他の費用JP¥2.00b収益-JP¥734.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-18.07グロス・マージン58.02%純利益率-33.64%有利子負債／自己資本比率0%7774 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 08:12終値2026/05/28 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Japan Tissue Engineering Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Hidemaru YamaguchiCitigroup IncKiyokazu YamazakiIchiyoshi Research Institute Inc.Shigekazu IshidaMarusan Securities Co. Ltd.1 その他のアナリストを表示
Reported Earnings • May 06Full year 2026 earnings released: JP¥18.07 loss per share (vs JP¥6.28 loss in FY 2025)Full year 2026 results: JP¥18.07 loss per share (further deteriorated from JP¥6.28 loss in FY 2025). Revenue: JP¥2.18b (down 11% from FY 2025). Net loss: JP¥734.0m (loss widened 188% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • May 01Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026.
Reported Earnings • Jan 31Third quarter 2026 earnings released: JP¥4.56 loss per share (vs JP¥3.08 loss in 3Q 2025)Third quarter 2026 results: JP¥4.56 loss per share (further deteriorated from JP¥3.08 loss in 3Q 2025). Revenue: JP¥511.0m (down 6.3% from 3Q 2025). Net loss: JP¥185.0m (loss widened 48% from 3Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
分析記事 • Dec 30Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is LackingThe Japan Tissue Engineering Co., Ltd. ( TSE:7774 ) share price has done very well over the last month, posting an...
分析記事 • Dec 29We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash BurnEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 06Full year 2026 earnings released: JP¥18.07 loss per share (vs JP¥6.28 loss in FY 2025)Full year 2026 results: JP¥18.07 loss per share (further deteriorated from JP¥6.28 loss in FY 2025). Revenue: JP¥2.18b (down 11% from FY 2025). Net loss: JP¥734.0m (loss widened 188% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • May 01Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026.
Reported Earnings • Jan 31Third quarter 2026 earnings released: JP¥4.56 loss per share (vs JP¥3.08 loss in 3Q 2025)Third quarter 2026 results: JP¥4.56 loss per share (further deteriorated from JP¥3.08 loss in 3Q 2025). Revenue: JP¥511.0m (down 6.3% from 3Q 2025). Net loss: JP¥185.0m (loss widened 48% from 3Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
分析記事 • Dec 30Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is LackingThe Japan Tissue Engineering Co., Ltd. ( TSE:7774 ) share price has done very well over the last month, posting an...
分析記事 • Dec 29We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash BurnEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 02Second quarter 2026 earnings released: JP¥3.17 loss per share (vs JP¥0.34 loss in 2Q 2025)Second quarter 2026 results: JP¥3.17 loss per share (further deteriorated from JP¥0.34 loss in 2Q 2025). Revenue: JP¥571.6m (down 21% from 2Q 2025). Net loss: JP¥128.6m (loss widened JP¥114.7m from 2Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 31First quarter 2026 earnings released: JP¥5.96 loss per share (vs JP¥5.20 loss in 1Q 2025)First quarter 2026 results: JP¥5.96 loss per share (further deteriorated from JP¥5.20 loss in 1Q 2025). Revenue: JP¥426.0m (down 3.7% from 1Q 2025). Net loss: JP¥242.0m (loss widened 15% from 1Q 2025). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Jul 21+ 2 more updatesJapan Tissue Engineering Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2026 results on Oct 31, 2025
Reported Earnings • Jun 24Full year 2025 earnings released: JP¥6.29 loss per share (vs JP¥3.52 profit in FY 2024)Full year 2025 results: JP¥6.29 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.3m (down 279% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 14Japan Tissue Engineering Co., Ltd. to Report Q1, 2026 Results on Jul 30, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2026 results on Jul 30, 2025
Reported Earnings • May 01Full year 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.52 profit in FY 2024)Full year 2025 results: JP¥6.28 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.0m (down 278% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 30Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025.
分析記事 • Apr 21Market Might Still Lack Some Conviction On Japan Tissue Engineering Co., Ltd. (TSE:7774) Even After 38% Share Price BoostJapan Tissue Engineering Co., Ltd. ( TSE:7774 ) shareholders would be excited to see that the share price has had a...
New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Apr 06Here's Why We're Not Too Worried About Japan Tissue Engineering's (TSE:7774) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Mar 20Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2025 Results on Apr 30, 2025Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2025 results on Apr 30, 2025
Reported Earnings • Feb 01Third quarter 2025 earnings released: JP¥3.08 loss per share (vs JP¥1.03 loss in 3Q 2024)Third quarter 2025 results: JP¥3.08 loss per share (further deteriorated from JP¥1.03 loss in 3Q 2024). Revenue: JP¥545.0m (up 1.1% from 3Q 2024). Net loss: JP¥125.0m (loss widened 198% from 3Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Dec 07Japan Tissue Engineering Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2025 results on Jan 31, 2025
Reported Earnings • Nov 02Second quarter 2025 earnings released: JP¥0.34 loss per share (vs JP¥0.59 loss in 2Q 2024)Second quarter 2025 results: JP¥0.34 loss per share (improved from JP¥0.59 loss in 2Q 2024). Revenue: JP¥718.7m (up 23% from 2Q 2024). Net loss: JP¥13.9m (loss narrowed 42% from 2Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Aug 31Japan Tissue Engineering Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2025 results on Oct 31, 2024
Reported Earnings • Aug 01First quarter 2025 earnings released: JP¥5.20 loss per share (vs JP¥0.32 profit in 1Q 2024)First quarter 2025 results: JP¥5.20 loss per share (down from JP¥0.32 profit in 1Q 2024). Revenue: JP¥442.0m (down 33% from 1Q 2024). Net loss: JP¥211.0m (down JP¥224.0m from profit in 1Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Aug 01Little Excitement Around Japan Tissue Engineering Co., Ltd.'s (TSE:7774) RevenuesJapan Tissue Engineering Co., Ltd.'s ( TSE:7774 ) price-to-sales (or "P/S") ratio of 10.1x might make it look like a...
Reported Earnings • Jun 23Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023)Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023)Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Mar 06The Market Lifts Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares 35% But It Can Do MoreJapan Tissue Engineering Co., Ltd. ( TSE:7774 ) shareholders have had their patience rewarded with a 35% share price...
お知らせ • Mar 03Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2024Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2024 results on Apr 30, 2024
Reported Earnings • Feb 02Third quarter 2024 earnings released: JP¥1.03 loss per share (vs JP¥5.02 loss in 3Q 2023)Third quarter 2024 results: JP¥1.03 loss per share (improved from JP¥5.02 loss in 3Q 2023). Revenue: JP¥539.0m (up 14% from 3Q 2023). Net loss: JP¥42.0m (loss narrowed 79% from 3Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Dec 01Japan Tissue Engineering Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2024 results on Jan 30, 2024
Reported Earnings • Nov 02Second quarter 2024 earnings released: JP¥0.59 loss per share (vs JP¥3.77 loss in 2Q 2023)Second quarter 2024 results: JP¥0.59 loss per share (improved from JP¥3.77 loss in 2Q 2023). Revenue: JP¥584.0m (up 6.2% from 2Q 2023). Net loss: JP¥24.0m (loss narrowed 84% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 01Japan Tissue Engineering Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2024 results on Oct 31, 2023
Reported Earnings • Aug 01First quarter 2024 earnings released: EPS: JP¥0.32 (vs JP¥6.60 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.32 (up from JP¥6.60 loss in 1Q 2023). Revenue: JP¥662.0m (up 57% from 1Q 2023). Net income: JP¥13.0m (up JP¥281.0m from 1Q 2023). Profit margin: 2.0% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Jun 18Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022)Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 11Japan Tissue Engineering Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023
Reported Earnings • Apr 29Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022)Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jan 28Third quarter 2023 earnings released: JP¥5.03 loss per share (vs JP¥1.80 loss in 3Q 2022)Third quarter 2023 results: JP¥5.03 loss per share (further deteriorated from JP¥1.80 loss in 3Q 2022). Revenue: JP¥471.4m (down 23% from 3Q 2022). Net loss: JP¥204.3m (loss widened 180% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 28Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 1,971 million. Operating loss to be JPY 787 million. Net loss to be JPY 789 million. Net loss per share to be JPY 19.43.
お知らせ • Dec 05Japan Tissue Engineering Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2023 results on Jan 31, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Toshiyuki Masai was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 01Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 2,540 million. Operating loss to be JPY 389 million. Net loss to be JPY 388 million. Net loss per share to be JPY 9.57.
Reported Earnings • Nov 01Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: JP¥550.2m (up 9.6% from 2Q 2022). Net loss: JP¥153.4m (loss widened 11% from 2Q 2022).
お知らせ • Sep 02Japan Tissue Engineering Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2023 results at 3:00 PM, Tokyo Standard Time on Oct 31, 2022
Reported Earnings • Jul 28First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: JP¥422.7m (down 12% from 1Q 2022). Net loss: JP¥268.2m (loss widened 108% from 1Q 2022).
お知らせ • Jul 28Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the period, the company expected net sales of JPY 2,540 million, operating loss of JPY 389 million, net loss of JPY 388 million and net loss per share of JPY 9.57.
Price Target Changed • Jul 23Price target decreased to JP¥1,200Down from JP¥1,760, the current price target is provided by 1 analyst. New target price is 95% above last closing price of JP¥615. Stock is down 14% over the past year. The company posted a net loss per share of JP¥12.24 last year.
Reported Earnings • Jun 19Full year 2022 earnings released: JP¥12.26 loss per share (vs JP¥11.48 loss in FY 2021)Full year 2022 results: JP¥12.26 loss per share (down from JP¥11.48 loss in FY 2021). Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 10Japan Tissue Engineering Co., Ltd. to Report Q1, 2023 Results on Jul 27, 2022Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2023 results at 3:00 PM, Tokyo Standard Time on Jul 27, 2022
お知らせ • Apr 27Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023Japan Tissue Engineering Co., Ltd. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of ¥2,540 million, operating loss of ¥389 million and net loss of ¥388 million or ¥9.57 per share.
Reported Earnings • Apr 27Full year 2022 earnings releasedFull year 2022 results: Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021).
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Managing Executive Officer & Director Hiroaki Kaneko was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 08Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2022 Results on Apr 26, 2022Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2022 results on Apr 26, 2022
Reported Earnings • Feb 01Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: JP¥615.5m (up 32% from 3Q 2021). Net loss: JP¥73.6m (loss narrowed 47% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 01Japan Tissue Engineering Co., Ltd. Announces Earnings Guidance for the Fiscal Year Ending March 31, 2022Japan Tissue Engineering Co., Ltd. announced earnings guidance for the fiscal year ending March 31, 2022. For the full Fiscal Year, the company expects sales of JPY 2,260 million, Operating loss of JPY 450 million, net loss of JPY 449 million and net loss per share of JPY 11.06.
お知らせ • Nov 25Japan Tissue Engineering Co., Ltd. Announces Start of Clinical Trial for Allogeneic Cultured EpidermisJapan Tissue Engineering Co., Ltd. announced that it submitted notification of the clinical trial plan for Allogeneic Cultured Epidermis (development name: "Allo-JaCE03") to the Pharmaceuticals and Medical Devices Agency today. J-TEC will acquire knowledge and know-how about medical devices through the development of "Allo-JaCE03" and develop new business in fields that use allogeneic cells (cells from other people). With the vision of "creating a future for regenerative medicine", J-TEC is promoting the creation of a regenerative medicine industry and contributing to the improvement of patient quality of life (QOL) by continuously developing and marketing new regenerative medical products and medical devices, in addition to promoting the spread of J-TEC's existing products. " Allo-JaCE03" is dried epidermal cell sheet derived from healthy human skin. Through reconstitution, it returns to the resilient physical properties it had before drying. Its high degree of biocompatibility makes it suitable for use in the promotion of early wound healing. Clinical Trial Summary: The purpose of this clinical trial is to verify the efficacy and confirm the safety of "Allo-JaCE03" in patients with deep dermal burn (DDB), which is a typical skin defect disorder. J-TEC plans to conduct the clinical trial at a total of 5 facilities, including Kyoto University Hospital. Product Features: Because the raw material is allogeneic cells, systematic mass-production of a product that meets certain quality standards is possible. The dried form of this cultured product means that it can be stored at room temperature for long periods of time. Medical institutions can stock it as a ready-made product (one that is manufactured and stored in advance so that it can be used without delay when needed). This product is a medical device that does not contain living cells. J-TEC is taking advantage of the product features of allogeneic origin and dried form to accelerate deployment not only within Japan but also to overseas markets.
Reported Earnings • Oct 31Second quarter 2022 earnings released: JP¥3.40 loss per share (vs JP¥2.41 loss in 2Q 2021)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2022 results: Revenue: JP¥502.0m (down 6.9% from 2Q 2021). Net loss: JP¥138.0m (loss widened 41% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 16Japan Tissue Engineering Co., Ltd. Announces Approval of Autologous Cultured Oral Mucosal Epithelium Ocural for NHI ListingJapan Tissue Engineering Co., Ltd. announces the approval of Autologous Cultured Oral Mucosal Epithelium "Ocural" for inclusion in the National Health Insurance price list effective December 1, 2021, at the general meeting of Central Social Insurance Medical Council (Chuikyo) held today. Ocural" is expected to be of benefit as a new treatment method for patients who have had marked declines in visual acuity owing to extensive corneal damage from limbal stem cell deficiency. With the corporate vision of "creating a future for regenerative medicine", J-TEC is building a regenerative medicine industry while contributing to the improvement of patients' quality of life (QOL) by continually developing and launching new regenerative medical products in addition to promoting the spread of its existing products.
Reported Earnings • Jul 31First quarter 2022 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: JP¥478.3m (up 27% from 1Q 2021). Net loss: JP¥129.5m (loss narrowed 26% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.
お知らせ • Jun 18Japan Tissue Engineering Co., Ltd. Announces Approval Obtained for Autologous Cultured Oral Mucosal Epithelium “Ocural”Japan Tissue Engineering Co., Ltd. announce that marketing approval was obtained for Autologous Cultured Oral Mucosal Epithelium "Ocural" on June 11, 2021. "Ocural" is a product for the treatment of limbal stem cell deficiency, and it is the world's first regenerative medical product using oral mucosal epithelial cells to treat this disease. This product will be manufactured in Japan and was developed through the practical application of technology developed by Prof. Kohji Nishida of the Department of Ophthalmology, Osaka University Graduate School of Medicine. It will be Japan's second regenerative medical product in the ophthalmology field, following Autologous Cultured Corneal Epithelium "Nepic", for which marketing approval was obtained in March 2020. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for Autologous Cultured Epidermis "JACE", which became Japan's first regenerative medical product, in 2007, and began marketing it in 2009. J-TEC went on to obtain marketing approval for Autologous Cultured Cartilage "JACC" in 2013 and Autologous Cultured Corneal Epithelium "Nepic" in March of 2020. "JACC" and "Nepic" were Japan's first regenerative medical products in the orthopedic surgery and ophthalmology fields, respectively. Through the practical application of "Ocural" in addition to "Nepic", J-TEC has made it possible to provide therapies for corneal epithelial diseases, for which curative treatment methods previously did not exist. J-Tec is promoting the industrialization of regenerative medicine and contributing to the improvement of patients' quality of life (QOL) by further strengthening sales of its existing products and accelerating the development of new regenerative medical products.
お知らせ • May 25Japan Tissue Engineering Co., Ltd. Announces Marketing Approval of Autologous Cultured Oral Mucosal Epithelial Cell SheetJapan Tissue Engineering Co., Ltd. announced that marketing approval of autologous cultured oral mucosal epithelial cell sheet (Development Name: COMET01) for the treatment of limbal stem cell deficiency (LSCD) *1 has been reviewed and acknowledged at today's meeting of the Regenerative Medical Products and Biological Technology Subcommittee of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council. COMET01 is epithelial cell sheet derived from human (autologous) oral mucosa. It is prepared by harvesting oral mucosal tissue from the patient and then cultivating the isolated cells. The purpose of this product is to repair defective corneal epithelium by transplanting the sheet onto the ocular surface, where the patient's own oral mucosal epithelial cells become engrafted and epithelialize. COMET01 is a promising new treatment method for patients who have extensive damage to the cornea of both eyes and markedly reduced visual acuity owing to LSCD. COMET01 was designated a regenerative medical product for orphan diseases *2 -- specifically the treatment of LSCD -- in 2020. J-TEC introduced the transplantation technique for autologous cultured oral mucosal epithelial cell sheets developed by Professor Kohji Nishida of Graduate School of Medicine/Faculty of Medicine, Osaka University (Department of Neural and Sensory Organ Surgery (Department of Ophthalmology)) and has taken over the investigator-initiated trial conducted by Professor Nishida's group, conducting it in the form of a company-sponsored clinical trial of COMET01 since September of 2016. In September of 2020, J-TEC submitted an application for marketing approval of COMET01to the Ministry of Health, Labour and Welfare as Japan's second regenerative medical product in the ophthalmology field. Marketing of COMET01 is to be conducted by Nidek Co., Ltd. (Gamagori City, Aichi Prefecture; President and CEO, Motoki Ozawa), a maker of ophthalmology and optometry products. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for autologous cultured epidermis "JACE", Japan's first regenerative medical product, in 2007 and began marketing JACE in 2009. Marketing approval was then obtained for autologous cultured cartilage "JACC" in 2013 and for autologous cultured corneal epithelium "NEPIC" *3 in March of 2020. JACC was Japan's first regenerative medical product in the orthopedic surgery field, and NEPIC was the first in the ophthalmology field. Through the practical application of first NEPIC and then COMET01, J-TEC has succeeded in providing a treatment method for corneal epithelial diseases for which no curative therapy previously existed. By reinforcing sales of existing products and accelerating development of new regenerative medical products, J-TEC is promoting the development of regenerative medicine into an industry while also contributing to the improvement of patients' quality of life (QOL).
Reported Earnings • May 01Full year 2021 earnings released: JP¥11.48 loss per share (vs JP¥7.07 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: JP¥2.26b (down 2.3% from FY 2020). Net loss: JP¥466.0m (loss widened 62% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Mar 04New 90-day high: JP¥802The company is up 24% from its price of JP¥649 on 04 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.
分析記事 • Feb 02We Think Japan Tissue Engineering (TYO:7774) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Feb 01Third quarter 2021 earnings released: JP¥3.40 loss per share (vs JP¥2.24 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥466.4m (down 11% from 3Q 2020). Net loss: JP¥137.9m (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 01New 90-day high: JP¥739The company is up 12% from its price of JP¥662 on 02 November 2020. The Japanese market is also up 12% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 10.0% over the same period.
お知らせ • Dec 19Japan Tissue Engineering Co., Ltd. to Report Q3, 2021 Results on Jan 29, 2021Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2021 results on Jan 29, 2021
Reported Earnings • Nov 01First half earnings releasedOver the last 12 months the company has reported total losses of JP¥288.0m, with losses widening by 52% from the prior year. Total revenue was JP¥2.24b over the last 12 months, down 3.2% from the prior year.
お知らせ • Sep 06Japan Tissue Engineering Co., Ltd. to Report Q2, 2021 Results on Oct 30, 2020Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2021 results on Oct 30, 2020
お知らせ • Aug 04Japan Tissue Engineering Co., Ltd. Do Not Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021Japan Tissue Engineering Co., Ltd. does not provided earnings guidance for the fiscal year ending March 31, 2021. The company announced that the 2019 novel coronavirus infection has spread worldwide and has a great impact on the business environment in Japan and overseas. Since there are many uncertainties that will affect the company's business due to the spread of infection, it is difficult to reasonably calculate the business forecast for the fiscal year ending March 2021 at this point. The company will make an announcement as soon as the situation has settled and it is possible to calculate the earnings forecast.
お知らせ • Jun 28Japan Tissue Engineering Co., Ltd. to Report Q1, 2021 Results on Jul 30, 2020Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2021 results on Jul 30, 2020
